Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Highly sensitive wastewater surveillance of SARS-CoV-2 variants by targeted next-generation amplicon sequencing provides early warning of incursion in Victoria, Australia.
Merrett JE, Nolan M, Hartman L, John N, Flynn B, Baker L, Schang C, McCarthy D, Lister D, Cheng NN, Crosbie N, Poon R, Jex A. Merrett JE, et al. Among authors: crosbie n. Appl Environ Microbiol. 2024 Aug 21;90(8):e0149723. doi: 10.1128/aem.01497-23. Epub 2024 Jul 16. Appl Environ Microbiol. 2024. PMID: 39012098 Free PMC article.
Agonistic anti-DCIR antibody inhibits ITAM-mediated inflammatory signaling and promotes immune resolution.
Chen L, Patil S, Barbon J, Waire J, Laroux S, McCarthy D, Pratibha M, Zhong S, Dong F, Orsi K, Nguyen G, Yang Y, Crosbie N, Dominguez E, Deora A, Veldman G, Westmoreland S, Jin L, Radstake T, White K, Wei HJ. Chen L, et al. Among authors: crosbie n. JCI Insight. 2024 May 23;9(12):e176064. doi: 10.1172/jci.insight.176064. JCI Insight. 2024. PMID: 38781017 Free PMC article.
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Tivey A, Shotton R, Eyre TA, Lewis D, Stanton L, Allchin R, Walter H, Miall F, Zhao R, Santarsieri A, McCulloch R, Bishton M, Beech A, Willimott V, Fowler N, Bedford C, Goddard J, Protheroe S, Everden A, Tucker D, Wright J, Dukka V, Reeve M, Paneesha S, Prahladan M, Hodson A, Qureshi I, Koppana M, Owen M, Ediriwickrema K, Marr H, Wilson J, Lambert J, Wrench D, Burney C, Knott C, Talbot G, Gibb A, Lord A, Jackson B, Stern S, Sutton T, Webb A, Wilson M, Thomas N, Norman J, Davies E, Lowry L, Maddox J, Phillips N, Crosbie N, Flont M, Nga E, Virchis A, Camacho RG, Swe W, Pillai A, Rees C, Bailey J, Jones S, Smith S, Sharpley F, Hildyard C, Mohamedbhai S, Nicholson T, Moule S, Chaturvedi A, Linton K. Tivey A, et al. Among authors: crosbie n. Blood Adv. 2024 Mar 12;8(5):1209-1219. doi: 10.1182/bloodadvances.2023011152. Blood Adv. 2024. PMID: 38127279 Free PMC article.
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D. Villa D, et al. Among authors: crosbie n. Blood Adv. 2023 Aug 22;7(16):4576-4585. doi: 10.1182/bloodadvances.2023009804. Blood Adv. 2023. PMID: 37307169 Free PMC article.
42 results